Millipore and CXR Biosciences Announce New Drug Screening Platform Products
6 Mar 2007Millipore Corporation in collaboration with CXR Biosciences Ltd. today announced their first jointly developed products for the pre-clinical drug development marketplace.
Announced as a joint co-development agreement in 2005 (with Upstate), this partnership strengthens Millipore’s increasing presence in the preclinical drug testing market and launches CXR’s entry into the reagent industry.
These products, several of which address unmet market needs, are antibodies that identify key enzymes and transcription factors important in drug metabolism and its regulation. The product portfolio includes:
Human Cytochrome P450 CYP2D6
Human Cytochrome P450 CYP2A6
Human Cytochrome P450 Reductase (POR)
Human Pregnane X Receptor (PXR)
Human Constitutive Androstane receptor (CAR)
Human Farnesoid X Receptor (FXR) (27 to 143)
Human Farnesoid X Receptor (FXR) (322 to 472)
This product platform enables safe drug compounds to be identified sooner and allows only the molecules most likely to succeed in the clinic to advance. Early compound identification makes it possible to reduce the development time for new therapies. Future co-development efforts will be focused on building predictive toxicity and drug metabolism screens to profile compounds in various cell based and in vitro assays.
Millipore’s Bioscience Division provides innovative tools, services and biological reagents that drive advancements in biomedical and academic research as well as support the discovery and development of new pharmaceuticals. The product portfolio has been further enhanced with the 2006 addition of Chemicon®, Upstate® and Linco® product lines, allowing Millipore to provide the most complete offering of life science tools on the market. Our customers work in leading research laboratories across a variety of industries throughout the world. Millipore improves their laboratory productivity and efficiency through optimized workflows.